Kura Oncology Inc. (KURA) Upgraded to “Hold” at Zacks Investment Research
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Separately, Oppenheimer Holdings Inc. reaffirmed an outperform rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Sunday, August 14th.
Shares of Kura Oncology (NASDAQ:KURA) traded up 2.508% during trading on Wednesday, reaching $6.745. The company had a trading volume of 2,800 shares. The firm has a 50-day moving average price of $5.91 and a 200-day moving average price of $4.06. Kura Oncology has a 52-week low of $2.50 and a 52-week high of $25.00. The company’s market capitalization is $126.42 million.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, analysts predict that Kura Oncology will post ($1.58) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC acquired a new position in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned approximately 0.34% of Kura Oncology as of its most recent filing with the SEC. 43.63% of the stock is owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.